摘要
目的：Her2是一种具有酪氨酸激酶活性的跨膜糖蛋白,它的过表达与肿瘤形成、恶性程度及预后密切相关。本研究的目的是通过构建全人源大容量噬菌体抗体库从而筛选鉴定具有高效抗肿瘤活性的Her2全人源抗体。方法：本实验构建了全人源大容量噬菌体抗体库,表达纯化了人Her2膜外区蛋白(Her2ECD),并利用Her2 ECD对噬菌体抗体库进行筛选,获得了异性结合Her2的噬菌体单链抗体ScFv,并构建完整L/pcDNA3.1(+)和H/pcDNA3.1(+)表达载体,在真核细胞CHO细胞中成功地表达了抗Her2抗体并对它们的体外抗肿瘤作用进行了研究。结果：我们制备的Her2抗体在体外能有效抑制乳腺癌细胞的MAPK、Akt信号通路,抑制Her2高表达乳腺癌细胞系SK-BR-3和BT-474的生长。结论：通过噬菌体抗体库的筛选,我们获得了具有抗肿瘤活性的Her2全人源抗体。
Objective:Her2 is a tyrosine kinase activity transmembrane glycoprotein, and its overexpression has relationship with tumor formation, the degree of malignancy and prognosis. In this study, we aim to prepare fully human anti-HER2 antibodies with potent antitumor activity. Methods:We constructed a large-capacity human ScFv phage antibody library and selected ScFv specific for HER2. Then the antibody expression vectors were constructed and anti-Her2 antibodies were expressed in CHO cells. Finally, we investigated the in vitro antitumor effects of these anti-Her2 antibodies on breast cancer cell lines. Results:Anti-Her2 antibodies could effectively inhibit the growth of Her2 high expresstion breast cancer cell lines SK-BR-3 and BT-474 in vitro. Conclusion:The present study provides several fully human anti-Her2 antibodies with potent antitumor activity and these anti-Her2 antibodies may serve as potential therapeutic agents for breast cancer.
引文
[1]. Smith, G.P. Filamentous fusion phage:novel expression vectors that display cloned antigens on the virion surface. Science,1985,228(4705):1315-1317.
[2]Slamon DJ,Clark GM,Wong SG,et al.Human breast cancer:correlation of relapse and survival with amplification of theHER-2/neuoncogene.Science,1987,235(4785):1772-182.
[3].Vander Geer P,Hunter T,Lindberg RA.Recptor protein-tyrosine Kinases and their single transduction pathway.Ann Revell Biol,1994,10:251-337.
[4].韩新华,孙超,韩愈。乳腺浸润性导管癌nm23和C-erbB-2的表达与淋巴结转关系的研究.南通医学院学报,2000,20(2)：150-152.
[5].At wells and wells JA. Selection for improved subtiligases display. Narl. acad. sci.USA,1999,96:947-950.
[6].Pereboeva LA, Pereboev AV, Wang LF, et al. Hepatitis C epitopes from phage-displayed cDNA libraries and improved diagnosis with achmeric antigen. J.Med. Virol 2000,60:144-151.
[7]. Sblattero D, Bradbury A. Exploiting recombination in single bacteria to make large phage antibody libraries. Nat Biotechnol,2000,18:74-80.
[8]Griffiths AD, Williams SC, Hartley O, et al. Isolation of high affinity human antibodies directly from large synthetic repertoire. EMBO J,1994,13:3245-3260.
[9].Vieira, J. and J. Messing. Production of single-stranded plasmid DNA. Methods Enzymol,1987,153:3-11.
[10]Reichert JM. Therapeutic monoclonal antibodies:Trends in development and app roval in the US [J]. CurrOpin M ol Ther,2002,4 (2):110-118.
[11]乔媛媛,王琰,陈晓穗,等.大容量噬菌体抗体库的构建及鉴定[J].中华微生物学和免疫学杂志,2004,24(3)：194-197.
[12]Sblattero D, Bradbury A. Exp loiting recombination in single bacteria to make large phage antibody libraries[J]. Nat B iotechnol,2000,18(1):74-79.
[13]王琰,刘群英,化冰,等.从人源性噬菌体抗体库分离出1株含有异常序列的抗HBsAg Fab克隆[J].中国免疫学杂志,1998,14(1)：115-119.
[14]王雷,王刚,等.从噬菌体抗体库筛选人源性抗白细胞介素8抗体[J].细胞与分子免疫学杂志,2005,21(2)：185-187.
[15]Weight A, Shin SU, Morrison SI. Genetically engineered antibodies:progress and p rospect[J]. Crit Rev Imm unol,1992,12 (3-4):125-131.
[16]BaylyAM, KorttAA, Hudson PJ. et al. Large2scale bacterial fermentation and isolation of scFv multimers using a heat2inducible bacterial
[17].Crosby, A.H., S.J. Edwards, J.C. Murray, et al. Genomic organization of the human osteopontin gene:exclusion of the locus from a causative role in the pathogenesis of dentinogenesis imperfecta type Ⅱ. Genomics,1995,27(1):155-160.
[18].Wrana, J.L., Q. Zhang, and J. Sodek.Full length cDNA sequence of porcine secreted phosphoprotein-Ⅰ (SPP-Ⅰ, osteopontin). Nucleic Acids Res,1989,17(23):10119.
[19].Tezuka, K., T. Sato, H. Kamioka, et al. Identification of osteopontin in isolated rabbit osteoclasts. Biochem Biophys Res Commun,1992,186(2):911-917.
[20].Oldberg, A., A. Franzen, and D. Heinegard. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A,1986,83(23):8819-8823.
[21]. Craig, A.M., J.H. Smith, and D.T. Denhardt. Osteopontin, atransformation-associated cell adhesion phosphoprotein, is induced by 12-O-tetradecanoylphorbol 13-acetate in mouse epidermis. J Biol Chem,1989, 264(16):9682-9689.
[22]. Moore, M.A., Y. Gotoh, K. Rafidi, et al. Characterization of a cDNA for chicken osteopontin:expression during bone development, osteoblast differentiation, and tissue distribution. Biochemistry,1991,30(9):2501-2508.
[23]王欲晓,周丽君,等.从大容量抗体库中筛选抗蓖麻毒蛋白抗体[J].中国免疫学杂志,2007,23(10)：924-927.
[24].Zhou, H., R.J. Fisher, and T.S. Papas. Optimization of primer sequences for mouse scFv repertoire display library construction. Nucleic Acids Res,1994,22(5):888-889.
[25].Coppola, D., M. Szabo, D. Boulware, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res,2004,10(1 Pt 1):184-190.
[26].Gao, C., H. Guo, L. Downey, et al. Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis,2003,24(12):1871-1878.
[27].Tuck, A.B., D.M. Arsenault, F.P. O'Malley, et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene,1999,18(29):4237-4246.
[28].Chambers, A.F., S.M. Wilson, N. Kerkvliet, et al. Osteopontin expression in lung cancer. Lung Cancer,1996,15(3):311-323.
[29].Kleinman, J.G., E.M. Worcester, A.M. Beshensky, et al. Upregulation of osteopontin expression by ischemia in rat kidney. Ann N Y Acad Sci,1995,760:321-323.
[30].Padanilam, B.J., D.R. Martin, and M.R. Hammerman. Insulin-like growth factor I-enhanced renal expression of osteopontin after acute ischemic injury in rats. Endocrinology,1996,137(5):2133-2140.
[31].Khan, S.A., C.A. Lopez-Chua, J. Zhang, et al. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem,2002,85(4): 728-736.
[32].Kroemer, G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med, 1997,3(6):614-620.
[33].Shijubo, N., T. Uede, S. Kon, et al.Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog,2000,11(2):135-146.
[34].Shijubo, N., T. Uede, S. Kon, et al. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med,1999,160(4): 1269-1273.
[35].Takagi, H., K. Suzuma, A. Otani, et al. Role of vitronectin receptor-type integrins and osteopontin in ischemia-induced retinal neovascularization. Jpn J Ophthalmol,2002, 46(3):270-278.
[36].Peek, M.J., T.M. Norman, C. Morgan, et al. The chick chorioallantoic membrane assay:an improved technique for the study of angiogenic activity. Exp Pathol,1988, 34(1):35-40.
[37].Ribatti, D., B. Nico, A. Vacca, et al.The gelatin sponge-chorioallantoic membrane assay. Nat Protoc,2006,1(1):85-91.
[38].Nguyen, M., Y. Shing, and J. Folkman.Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc Res,1994, 47(1):31-40.
[39].Gimbrone, M.A., Jr., R.S. Cotran, S.B. Leapman, et al. Tumor growth and neovascularization:an experimental model using the rabbit cornea. J Natl Cancer Inst, 1974,52(2):413-427.
[40].Ziche, M., G. Alessandri, and P.M. Gullino. Gangliosides promote the angiogenic response. Lab Invest,1989,61(6):629-634.
[41].Kenyon, B.M., E.E. Voest, C.C. Chen, et al.A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci,1996,37(8):1625-1632.
[42]. Jain. R.K., K. Schlenger, M. Hockel. et al. Quantitative angiogenesis assays:progress and problems. Nat Med,1997,3(11):1203-1208.70. Folkman, J. and M. Klagsbrun.Angiogenic factors. Science,1987,235(4787):442-447.
[43].Hori, K., M. Suzuki, S. Tanda, et al.Characterization of heterogeneous distribution of tumor blood flow in the rat. Jpn J Cancer Res,1991,82(1):109-117.
[44].Takano, S., K. Tsuboi, Y. Tomono. et al. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer,2000,82(12):1967-1973.
[45].Soga, N., J.O. Connolly, M. Chellaiah, et al. Rac regulates vascular endothelial growth factor stimulated motility. Cell Commun Adhes,2001,8(1):1-13.
[46].Patarca, R., G.J. Freeman, R.P. Singh, et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med,1989, 170(1):145-161.
[47].Sodek, J., B. Ganss, and M.D. McKee.Osteopontin. Crit Rev Oral Biol Med,2000, 11(3):279-303.
[48].Katagiri, Y.U., J. Sleeman, H. Fujii, et al. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res,1999,59(1):219-226.
[49].Thayer, J.M. and GC. Schoenwolf. Early expression of Osteopontin in the chick is restricted to rhombomeres 5 and 6 and to a subpopulation of neural crest cells that arise from these segments. Anat Rec,1998,250(2):199-209.
[50].Suzuki, K. [Osteopontin-gene, structure and biosynthesis]. Nippon Rinsho,2005,63 Suppl 10:608-612.
[51].Thompson, J.D., D.G. Higgins, and T.J. Gibson. CLUSTAL W:improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res,1994, 22(22):4673-4680.
[52].Ganss, B., R.H. Kim, and J. Sodek.Bone sialoprotein. Crit Rev Oral Biol Med,1999, 10(1):79-98.
[53].Chang, P.L., M. Cao, and P Hicks. Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells. Carcinogenesis,2003, 24(11):1749-1758.
[54].Philip, S., A. Bulbule, and G.C. Kundu. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem,2001,276(48):44926-44935.
[55].Fedarko, N.S., A. Jain, A. Karadag, et al. Three small integrin binding ligand N-linked glycoproteins (SIBLINGS) bind and activate specific matrix metalloproteinases. Faseb J,2004,18(6):734-736.
[56].Aznavoorian, S., A.N. Murphy, W.G. Stetler-Stevenson, et al. Molecular aspects of tumor cell invasion and metastasis. Cancer,1993,71(4):1368-1383.
[57].Angelucci, A., C. Festuccia, GL. Gravina, et al. Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. Prostate,2004,59(2):157-166.
[58].Baselga J.Clinical trials of Herceptin (trastuzumab) [J]. Eur J Cancer,2001,37 (Suppll):18-24.
[59]Xu G, Zhang W, Bertram P, et al. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors[J]. Int J Oncol,2004, 24(4):893-900.
[60]Vivanco I, Sawyers CL. Pharmacogenomic profiling of the PI3K/PTEN-AKT mTOR pathway in common human tumors [J]. Nat Rev Cancer,2002,2(7):489-501.
[61]Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma [J]. Oncogene,2002,21(43):6587-6597.
[62]Hill MM, Hemmings BA.Inhibition of protein kinase B/Akt implications for cancer therapy [J]. Phamacol Ther,2002,93(2-3):243-251.
[63]Huang S, Houghton PJ. Targetiog mTOR signaling for cancer therapy[J]. Curr Opin Pharmacol,2003,3(4):371-377.
[64].Barltrop, J.A. et al.5-(3-carboxymethoxyphenyl)-2-(4,5-dimenthylthiazoly)-3-(4-sulfophenyl) etrazolium, inner salt (MTS) and related analogs of 3-(4, 5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT) reducing topurple water soluble formazans as cell-viability indicators.Bioorg. Med. Chem. Lett.1991, 611-614.
[65].Berridge, M.V. and Tan, A.S.Characterization of the cellular reduction of3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): Subcellularlocalization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch. Biochem Biophys.1993.303,474-482.
[66].Cory, A.H. et al. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture.Cancer Commun.1991,3,207-212.
[67].Riss, T.L. and Moravec, R.A. Comparison of MTT, XTT, and a novel tetrazolium compound for MTS for in vitro proliferation and chemosensitivity assays. Mol. Biol. Cell(Suppl) 1992,3,184a.
[68].Mosmann, T. Rapid colorimetric assay for cellular growth and survival:Application to proliferation and cytotoxicity assays. J. Immunol. Methods1983,65,55-63.
[69].Bernabei, P.A. et al.In vitro chemosensitivity testing of leukemic cells:Development of a semiautomated colorimetric assay.Hematol. Oncol.1989,7,243-253.
[70].Chen, C.-H. et al. MTT colorimetric assay detects mitogen responses of spleen but not blood lymphocytes. Int. Arch. Allergy Appl. Immunol.1990,93,249-255.
[71].Shak S. Overview of the Herceptin (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpression metastatic breast cancer [J].Semi Oncol, 1999,26:71-74.
[72].Kakonen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma [J].Cancer,2003,97(3Suppl):834-839.
[73].Pegram M D, Finn R S, Arzoo K, et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells [J]. Oncogene,1997,15:537-547.
[74].Burstein H J, Kuter Ⅰ, Campos S M. Clinical activity of Herceptin and vinorelbine in women with HER-2-overexpressingmetastatic breast cancer [J]. J Clin Oncol,2001,9: 2722-2730.
[75].Kunisue H, Kurebayashi J, Otsuki T, et al. Anti-HER-2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER-2 [J]. Br J Cancer,2000,82:46-51.
[76].CobleighM A, Vogel C L, TripathyD, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy formetastatic disease[J]. J Clin Oncol,1999,17:2639-2648.
[77].Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase Ⅲ study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. JClin Oncol,2006, 24:2786-2792.
[78].Baselga J. Clinical trials of Hercep tin (trastuzumab) [J].Eur J Cancer,2001,37 (Supp11):S18-S24.
[79].Mass RD, PressMF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with Herceptin. Clin Breast Cancer,2005,6:240-246.
[80].Nahta R, HungMC, Esteva FJ.The HER-2-targeting antibodies Herceptin and Pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res, 2004,64:2343-2346.
[81].NahtaR, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to Herceptin resistance of breast cancer cells. Cancer Res,2005,65:11118-11128.
[1]Tatyana A Grushko, M Anne Blaekwood, Phil L Schumm, et al. Molecular-cytogenetic analysis of HER-2/neu gene in BRCAI-associated breast cancers[J]. Cancer Rearch,2002,62:1481-1488.
[2]Coussens L, Yang-Fens TL, Liao YC, et al.Tyrosine kinase receptor with extensive homology to EGC receptor shares chromosomal location with neu oncogene [J]. Science,1985,230:1132-1139.
[3]Slamon DJ, Clark GM, Wang SG, et al. Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene [J]. Science, 1987,235:177-181.
[4]Lohrish C, PiccartM. An overview of HER-2 [J]. Semin Oncol,2001,28:3-11.
[5]WingensM,Walma T, Van Ingen H, et al. Structural analysis of an epi-dermal growth factor/transforming growth factoralpha chimera with unique ErbB binding specificity [J]. J Biol Chem,2003,278 (40):39114-39 123.
[6]TISEO M, LOPREV ITE M, ARD IZZON I A, et al. Epidermal growth factor receptor inhibitors:a new prospective in the treatment of lung cancer [J]. Curr Med Chem Anti-Canc Agents,2004,4 (2):139-148.
[7]Chen QQ, Chen XY, Jiang YY, et al. Identification of novel nuclear localization signal within the ErbB-2 protein. Cell Res,2005,15(7):504-510.
[8]MarmorMD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB /HER receptors[J]. Int J Radiat OncolBiol Phys,2004,58 (3):903-913.
[9]WingensM, Walma T, van Ingen H et al. Structural analysis of an epidermal growth factor/transforming growth factor-alpha chimera with unique ErbB binding specificity[J]. J Biol Chem,2003,278 (40):39114-39123.
[10]Ogiso H, Ishitani R, Nureki O et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular do-mains[J]. Cell,2002,110 (6):775-787.
[11]Cho HS, Leahy DJ. Structure of the extracellular region of HER3 reveals an interdomain tether[J]. Science,2002,297 (5585):1330-1333.
[12]Schlessinger J. Ligand2induced, receptor-mediated dimerization and activation of EGF receptor [J]. Cell,2002,110 (6):669-672.
[13]Segatto O, King CR, Pierce JH et al. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB22 gene[J]. Mol Cell Biol,1988,8 (12):5570-5574.
[14]袁向飞,陆敏.Ras/MAPK与PI3K/Akt言号转导通路及其相互作用[J].国际检验医学杂志,2006,27(3)：261-263.
[15]Johnson GL, Vaillancourt RR. Sequential protein kinase reactions controlling cell growth and differentiation[J]. Curr Opin Cell Biol,1994,6(2):230-238.
[16]Datta SR, Brunet A. Greenberg ME. Cellular survival:a play in three Akts[J]. Genes Dev,1999,13(22):2905-2927.
[17]Downward J.Mechanisms and consequences of activation of protein kinase B/Akt [J]. Curt Opin Cel Biol,1998,10(2):262-267.
[18]Zhou BP, Hung MC. Novel targets of Akt, p21(Cipl/WAF1), and MDM2[J]. Semin Oncol,2002,29(3 Suppl 11):62-70.
[19]GFossman SR, Perez M, Kung AL. P300/MDM2 complexes par-ticipate in MDM2-mediated P53 degradation[J]. Mol Cel,1998,2 (4):405-415.
[20]Lin SY, Xia W, Wang JC. Beta-tatenin, a novel prognostic marker for breast cancer:its roles in cyclinDl expression an d cancer progression [J]. Proc Natl Acad Sci USA,2000,97(8):4262-4266.
[21]Asada M, Yamada T, Ichijo H. Apoptosis inhibitory activity of cytoplasmie p21(cipl/WAF1)in monocytic differentiation [J]. EMBOJ,1999,18(5): 1223-1234.
[22]Luidn M, Bosque M, Mirapeix RM, et al. Late-onset congenital cystic adenomatoid malformation of the lung. Embryology, clinical symptomatology, diagnostic procedures, therapeutic approach and clinical follow-up[J]. Respiration,2002,69(2):148-154.
[23]Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function [J]. Oncogene,2000,19(21):2468-2473.
[24]Wingens M, Walma T, van Ingen H, et al. Structural analvsis of an epidermal growth factoralpha chimera with unique ErbB binding specificity [J]. J Biol Chem,2003,278(40):39114-39123.
[25]Schlessinger J. Cell signaling by receptor tyrosine kinases[J]. Cell,2000,103(2): 211-255.
[26]Daly RJ. Take your partners, please-signal diversification by the ErbB family of receptor tyrosine kinases[J]. Growth Factors,1999,16(4):255-263.
[27]Dowdy SC, Mariani A, Janknecht R. HER2/Neu and TAK1-mediated up-regulation of the transforming growth factor beta inhibitor Smad7 via the ETS protein ER81[J]. J Biol Chem,2003,278(45):44377-44384.
[28]Simeone AM, LiYJ, Broemeling LD, et al. Cyclooxygenase-2 is esential for HER2/neu to suppress N-(4-hydmxypheny1) retinamide efects in breast cancer cells [J]. Cancer Res,2004,64(4):1224-1228.
[29]Wang SC, Lien HC, Xia W, et al. Binding at an d transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2[J]. Cancer Cell,2004,6(3): 251-261.
[30]Winters ZE, Leek RD, Bradburn MJ, et al. Cytoplasmic p21 (WAF1/CIP1、 expression is correlated with HER-2/neu in breast cancer and is an independent predictor Of prognosis [J]. Breast Cancer Res,2003,5(6):242-249.
[31]Howe LR, Dannenberg AJ. COX-2 inhibitors for the prevention of breast cancer[J]. J Mammary Gland Biol Neoplasia,2003,8(1):31-43.
[32]Pellikainen JM, Ropponen KM, Kataja VV, et al. Expression of matrix Metalloproteinase(MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis[J]. Clin Cancer Res,2004,10(22): 7621-7628.
[33]Finkenzeller G, Weindel K, Zimmerm ann W, et al. Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Spl [J]. Angiogenesis,2004,7(1):59-68.
[34]Lin SY, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor[J]. Nat Cell Biol,2001,3(9): 802-808.
[35]Xu ZH, Ford BD. Upregulation of erbB receptors in rat brain after middle cerebral arterial occlusion [J]. Neurosci Lett,2005.375 (3):181-186.
[36]Souglakos J, Vamvakas L, Apostolaki S, et al. Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status[J]. Breast Cancer Res,2006,8(14):R36.
[37]Im SA, Lee KE, Nam E, et al. Potential prognostic significance of p185 (HER2) overexpression with loss of PTEN expression in gastric carcinomas [J]. Tumori, 2005,9(16):513-521.
[38]Rosty C, Couturier J, Vincent-Salomon A, et al. Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix[J]. Int J Gyne-col Pathol,2004,23 (1):13-17.
[39]Rebischung C, Barnoud R, Stefani L, et al. The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 protein [J]. Gastric Cancer,2005,8(4):249-252.
[40]Fujimoto N, WislezM, Zhang J, et al. High expression of ErbB familymembers and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor[J]. Cancer Res,2005,65 (24):11478-11485.
[41]D isisML, Schiffman K. Cancer vaccines targeting the HER2/neu oncogenic protein [J]. Sem in Oncol,2001,28 (6 Supp 118):12-20.
[42]Artufel MV, Valero AC, Llado RR, et al. Molecular protocol for HER2/neu analysis in breast carcinoma [J]. Clin Transl Oncol,2005,7 (11):504-511.
[43]Stonecypher MS, Chaudhury AR, Byer SJ, et al. Neuregulin growth factors and their ErbB receptors form a potential signaling network for schwannoma tumorigenesis. J Neuropathol Exp Neurol,2006,65(2) 162-175.
[44]魏兵.HER-2与乳腺癌：生物学特点、临床意义及检测[J].华西医学,2004,19：319-320.
[45]WANG SC, LIEN HC, XIA W, et al. Hung MC binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2[J]. Cancer Cell, 2004,6(3):251-261.
[46]GAL IEGUE S, CASELLAS P, KRAMAR A, et al. Immunohisto-Chemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival[J]. Clin Cancer Res,2004,10(6):2058-2064.
[47]KLEER CG, VAN GOLEN KL, BRAUN T,et al. Persistent E-cadherin expression in inflammatory breast cancer[J]. Mod Pathol,2001,14(5):458-464.
[48]KUNITOMO K, NOUE S, ICHIHARA F, et al. A case of metastatic breast cancer without growth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel [J].Hum Pathol,2004,35(3):379-381.
[49]Kakonen SM, Mundy GR. Mechanisms of osteolytic bone metastases in breast carcinoma [J].Cancer,2003,97(3Suppl):834-839.
[50]Gancberg D, Jarvinen T, di Leo A et al. Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry:an interlaboratory study assessing the reproducibility of HER-2/NEU testing [J]. Breast Cancer Res Treat,2002,74 (2):113-120.
[51]Hatanaka Y, Hashizume K, Kamihara Y et al. Quantitative immunohistoche-mical evaluation of HER2/neu expression with HercepT-estTM in breast carcinoma by image analysis[J]. Pathol Int,2001,51 (1):33-36.
[52]Yaziji H, Gown AM. Accuracy and precision in HER2/neu testing in breast cancer:are we there yet[J]. Hum Pathol,2004,35 (2):143-146.
[53]Arnould L, Denoux Y, MacGrogan G et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer [J]. Br J Cancer,2003,88(10):1587-1591.
[54]Carney WP, Neumann R, Lip ton A et al. Potential clinical utility of serum HER22/neu oncoprotein concentrations in patients with breast cancer [J]. Clin Chem,2003,49 (10):1579-1598.
[55]Gjerdrum LM, Sorensen BS, Kjeldsen E et al. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma:an alternative method for HER-2/neu analysis [J]. J Mol Diagn,2004,6(1):42-51.
[56]Mandal M, Adam L, Mendesohn J, et al. Nuclear targeting of Bax during apoptosisin human colorectal cancer cell. Oncogene,1998,17(8):999-1007.
[57]Yamauchi H, Stearns V, HayesDF. When is a tumor marker ready for prime time: a case study of cerbB-2 as a predictive factor in breast cancer.J Clin Oncol,2001, 19(8):2334-2356.
[58]Baselga J.Clinical trials of Herceptin (trastuzumab) [J]. Eur J Cancer,2001,37 (Suppll):18-24.
[59]Xu G, Zhang W, Bertram P, et al. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors[J]. Int J Oncol, 2004,24(4):893-900.
[60]Vivanco I, Sawyers CL. Pharmacogenomic profiling of the PI3K/PTEN-AKT mTOR pathway in common human tumors [J]. Nat Rev Cancer,2002,2(7): 489-501.
[61]Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma [J]. Oncogene.2002,21(43):6587-6597.
[62]Hill MM, Hemmings BA.Inhibition of protein kinase B/Akt implications for cancer therapy [J]. Phamacol Ther,2002,93(2-3):243-251.
[63]Huang S, Houghton PJ. Targetiog mTOR signaling for cancer therapy[J]. Curr Opin Pharmacol,2003,3(4):371-377.
[64]Zhou X, Tan M, Stone Hawthorne V, et al. Activation of the Akt/mammalian target of Rapamycin/4E-Bpl pathway by ErbB2 overexpression predicts tumor progression in breast cancers [J]. Clin Cancer Res,2004,10(20):6779-6788.
[65]Yakes FM, Chinratanalab W, Ritter CA,et al. Herceptininduced inhibition of Phosphatidylinositol-3 Kinase and Akt is required for antibody-mediated effects on p27, Cyclin Dl, and antitumor action[J].Cancer Res,2002,62(14): 4132-4141.
[66]Lane HA, Beuvink I, Motoyama AB, et al. ErbB2 potentiates breast tumor proliferation through modulation of p27Kipl-Cdk2 complex formation:receptor over expression does not determine growth dependency [J]. Mol Cell Biol,2000, 20(9):3210-3223.
[67]Gao N, Flynn DC, Zhang Z, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells [J]. Am J Physiol Cell Physiol,2004,287(2):C281-C291.
[68]Hanada M, Feng J, Hemmings BA.Structure, regulation and function of PKB/AKT-a major therapeutic target [J]. Biochem Biophys Acta,2004, 1697(1-2):3-16.
[69]Gao N, Zhang Z, Jiang BH, et al. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer[J]. Biochem Biophys Res Commun, 2003,310(4):1124-1132.
[70]Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kipl) by PKB/Akt-mediated phosphorylation in breast cancer[J]. Nat Med,2002,8(10):1136-1144.
[71]Shak S. Overview of the Herceptin (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpression metastatic breast cancer [J].Semi Oncol,1999,26:71-74.
[72]罗荣城,李爱民,张军一,等. Herceptin治疗Her-2过度表达的转移性乳腺癌[J].中华肿瘤杂志,2004,26：52-54.
[73]Pegram M D, Finn R S, Arzoo K, et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells [J]. Oncogene,1997,15:537-547.
[74]Burstein H J, Kuter 1, Campos S M. Clinical activity of Herceptin and vinorelbine in women with HER-2-overexpressingmetastatic breast cancer [J]. J Clin Oncol,2001,9:2722-2730.
[75]Kunisue H, Kurebayashi J, Otsuki T, et al. Anti-HER-2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER-2 [J]. Br J Cancer,2000,82:46-51.
[76]CobleighM A, Vogel C L, TripathyD, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy formetastatic disease[J]. J Clin Oncol,1999,17:2639-2648.
[77]Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. JClin Oncol,2006,24:2786-2792.
[78]Baselga J. Clinical trials of Hercep tin (trastuzumab) [J].Eur J Cancer,2001,37 (Supp11):S18-S24.
[79]Mass RD, PressMF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with Herceptin. Clin Breast Cancer,2005, 6:240-246.
[80]Nahta R, HungMC, Esteva FJ.The HER-2-targeting antibodies Herceptin and Pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res, 2004,64:2343-2346.
[81]NahtaR, Yuan LX, Zhang B, et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to Herceptin resistance of breast cancer cells. Cancer Res,2005,65:11118-11128.
[82]Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by Herceptin, and loss of PTEN predicts Herceptin resistance in patients. Cancer Cell,2004,6:117-127.
[83]Wang SE, Narasanna A, Perez-Torres M, et al. HER2/neu (erbB2) kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGF receptors. Proc Amer Assoc Cancer Res.2006,47:343-344.
[84]Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to Herceptin therapy in nonsmall-cell lung cancer. N Engl J Med,2006,354: 2619-2621.
[85]PrempeeT,Wongpaksa C. Mutations of HER2-positive metastatic breast cancer. Proc Am Soc Clin Oncol,2006,18S:611 s.
[86]Walshe JM, Denduluri N, Berman AW, et al. A phase Ⅱ trial with trastuzumab and Pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Clin Breast Cancer,2006,6:535-539.
[87]Wang P,Munger CM, Joshia D, et al. Cytotoxicity of cord blood derived Her2 /neu2specific cytotoxic T lymphocytes against human breast cancer in vitro and in vivo[J]. Breast Cancer Res and Treat,2004,83 (1):15-23.
[88]Peoples GE, Gurney JM, Hueman MT, et al. Clinical tri2al results of a HER2 /neu (E75) vaccine to p revent recurrence in high2risk breast cancer patients [J]. J Clinoncol,2005,23 (30):7536-7545.
[89]Jiang B, Liu W, Qu H, et al. A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER22 [J]. J Biol Chem,2005,280 (6):4656-4662.
[90]Chen Z, Huang H, Chang T, et al. Enhanced HER-2/neu2 specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor[J]. Cancer Gene Therapy,2002,9 (9):7782786.
[91]Kim JH, Majumder N, Lin H, et al. Enhanced immunity by NeuEDhsp70 DNA vaccine Is needed to combat an aggressive spontaneous metastatic breast cancer [J]. Molecular Therapy,2005,11 (6):941-949.
[92]Fabbro D, Ruetz S, Buchdunger E, et al. Protein kinases as targets for anticancer agents from inhibitors to useful drugs [J]. Pharmacol T2 her,2002,93 (2-3):79-98.
[93]任辉,张研,姜涛,等. HER2 xCD3双抗体治疗过度表达HER2基因裸鼠乳腺癌及其机制[J].中华实验外科杂志,2005,22(1)：46-48.
[94]Sen M,Wankowski DM, Garlie NK, et al. Use of anti2CD3 x anti-HER2/neu bispecifie antibody for redirecting cytotoxicity of activated T cells toward HER2 /neu+tumors[J]. Hematother Stem Cell Res,2001,10 (2):247-260.
[95]Wassenegger M. Gene silencing [M]. Int Rev Cytol,2002,219:61.
[96]Helguera G,Dela Cruz JS,Lowe C, et al. Vaccination with novel combinations of anti2HER2/neu cytokines fusion proteins and soluble protein antigen elicits a p rotective immune response against HER2/neu expressing tumors[J]. Vaccine, 2006,24 (3):304-316.
[97]Tovey S, Dunne B,Witton CJ, et al. Can molecular markers predict when to imp lement treatment with aromatase inhibitors in invasive breast cancer? [J]. Clin Cancer Res,2005,11 (13):4835-4842.
[98]Gago FE, FanelliMA, Ciocca DR. Co-expression of steroid hormone receptors (estrogen receptor alpha and/or p rogesterone receptors) and Her2 /neu (c-erbB-2) in breast cancer:clinical out2come following tamoxifen2based adjuvant therapy [J]. Steroid Biochem MolBiol,2006,98 (1):36-40.
[1].Senger, D.R., D.F. Wirth, and R.O. Hynes. Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell,1979,16(4):885-893.
[2]. Crosby, A.H., S.J. Edwards, J.C. Murray, et al. Genomic organization of the human osteopontin gene:exclusion of the locus from a causative role in the pathogenesis of dentinogenesis imperfecta type Ⅱ. Genomics,1995,27(1): 155-160.
[3].Smith, G.P. Filamentous fusion phage:novel expression vectors that display cloned antigens on the virion surface. Science,1985,228(4705):1315-1317.
[4].Denhardt, D.T. and X. Guo. Osteopontin:a protein with diverse functions. Faseb J, 1993,7(15):1475-1482.
[5].Reinholt, F.P., K. Hultenby, A. Oldberg, et al. Osteopontin--a possible anchor of osteoclasts to bone. Proc Natl Acad Sci U S A,1990,87(12):4473-4475.
[6].Leali, D., P. Dell'Era, H. Stabile, et al. Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol,2003,171(2):1085-1093.
[7].Senger, D.R., S.R. Ledbetter, K.P. Claffey, et al. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol,1996,149(1):293-305.
[8].Kiefer, M.C., D.M. Bauer, and P.J. Barr. The cDNA and derived amino acid sequence for human osteopontin. Nucleic Acids Res,1989,17(8):3306.
[9].Kerr, J.M., L.W. Fisher, J.D. Termine, et al. The cDNA cloning and RNA distribution of bovine osteopontin. Gene,1991,108(2):237-243.
[10].Wrana, J.L., Q. Zhang, and J. Sodek. Full length cDNA sequence of porcine secreted phosphoprotein-I (SPP-1, osteopontin). Nucleic Acids Res,1989,17(23): 10119.
[11].Tezuka, K., T. Sato, H. Kamioka, et al. Identification of osteopontin in isolated rabbit osteoclasts. Biochem Biophys Res Commun,1992,186(2):911-917.
[12].Oldberg, A., A. Franzen, and D. Heinegard. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A,1986,83(23):8819-8823.
[13].Craig, A.M., J.H. Smith, and D.T. Denhardt. Osteopontin, a transformation-associated cell adhesion phosphoprotein, is induced by 12-O-tetradecanoylphorbol 13-acetate in mouse epidermis. J Biol Chem,1989, 264(16):9682-9689.
[14].Moore, M.A., Y. Gotoh, K. Rafidi, et al. Characterization of a cDNA for chicken osteopontin:expression during bone development, osteoblast differentiation, and tissue distribution. Biochemistry,1991,30(9):2501-2508.
[15].Yokosaki, Y., N. Matsuura, T. Sasaki, et al. The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin. J Biol Chem,1999,274(51): 36328-36334.
[16].Prols, F., B. Loser, and M. Marx. Differential expression of osteopontin, PC4, and CEC5, a novel mRNA species, during in vitro angiogenesis. Exp Cell Res, 1998,239(1):1-10.
[17].Hirama, M., F. Takahashi, K. Takahashi, et al. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett,2003,198(1):107-117.
[18].Hamada, Y, K. Nokihara, M. Okazaki, et al. Angiogenic activity of osteopontin-derived peptide SVVYGLR. Biochem Biophys Res Commun,2003, 310(1):153-157.
[19].Thalmann, G.N., R.A. Sikes, R.E. Devoll, et al. Osteopontin:possible role in prostate cancer progression. Clin Cancer Res,1999,5(8):2271-2277.
[20].Adler, B., S. Ashkar, H. Cantor, et al. Costimulation by extracellular matrix proteins determines the response to TCR ligation. Cell Immunol,2001,210(1): 30-40.
[21].Gotoh, M., M. Sakamoto, K. Kanetaka, et al. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int,2002,52(1):19-24.
[22].Tuck, A.B. and A.F. Chambers. The role of osteopontin in breast cancer:clinical and experimental studies. J Mammary Gland Biol Neoplasia,2001,6(4): 419-429.
[23].Faccio, R., M. Grano, S. Colucci, et al. Activation of alphav beta3 integrin on human osteoclast-like cells stimulates adhesion and migration in response to osteopontin. Biochem Biophys Res Commun,1998,249(2):522-525.
[24].Bautista, D.S., J.W. Xuan, C. Hota, et al. Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem,1994,269(37):23280-23285.
[25].Hijiya. N., M. Setoguchi, K. Matsuura, et al. Cloning and characterization of the human osteopontin gene and its promoter. Biochem J,1994,303 (Pt 1): 255-262.
[26].Young, M.F., J.M. Kerr, J.D. Termine, et al. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics,1990,7(4):491-502.
[27].He, B., M. Mirza, and G.F. Weber. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene,2006,25(15): 2192-2202.
[28].Krebber, A., S. Bornhauser, J. Burmester, et al. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J Immunol Methods,1997, 201(1):35-55.
[29].Kettleborough, C.A., J. Saldanha, K.H. Ansell, et al. Optimization of primers for cloning libraries of mouse immunoglobulin genes using the polymerase chain reaction. Eur J Immunol,1993,23(1):206-211.
[30].Zhou, H., R.J. Fisher, and T.S. Papas. Optimization of primer sequences for mouse scFv repertoire display library construction. Nucleic Acids Res,1994, 22(5):888-889.
[31].Vieira, J. and J. Messing. Production of single-stranded plasmid DNA. Methods Enzymol,1987,153:3-11.
[32].Coppola, D., M. Szabo, D. Boulware, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res,2004,10(1 Pt 1):184-190.
[33].Gao, C., H. Guo, L. Downey, et al. Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis,2003,24(12):1871-1878.
[34].Tuck, A.B., D.M. Arsenault, F.P. O'Malley, et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene,1999,18(29):4237-4246.
[35].Chambers, A.F., S.M. Wilson, N. Kerkvliet, et al. Osteopontin expression in lung cancer. Lung Cancer,1996,15(3):311-323.
[36].Tuck, A.B., F.P. O'Malley, H. Singhal, et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med,1997,121(6):578-584.
[37].Agrawal, D., T. Chen. R. Irby, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst,2002,94(7):513-521.
[38].Kim, J.H., S.J. Skates, T. Uede, et al. Osteopontin as a potential diagnosticbiomarker for ovarian cancer. Jama,2002,287(13):1671-1679.
[39].Denhardt, D.T., C.A. Lopez, E.E. Rollo, et al. Osteopontin-induced modifications of cellular functions. Ann N Y Acad Sci,1995,760:127-142.
[40].Kleinman, J.G., E.M. Worcester, A.M. Beshensky, et al. Upregulation of osteopontin expression by ischemia in rat kidney. Ann N Y Acad Sci,1995,760: 321-323.
[41].Padanilam, B.J., D.R. Martin, and M.R. Hammerman. Insulin-like growth factor I-enhanced renal expression of osteopontin after acute ischemic injury in rats. Endocrinology,1996,137(5):2133-2140.
[42].Khan, S.A., C.A. Lopez-Chua, J. Zhang, et al. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem,2002,85(4):728-736.
[43].Kroemer, G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med,1997,3(6):614-620.
[44].Shijubo, N., T. Uede, S. Kon, et al. Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog,2000,11(2):135-146.
[45].Shijubo, N., T. Uede, S. Kon, et al. Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med,1999, 160(4):1269-1273.
[46].Takagi, H., K. Suzuma, A. Otani, et al. Role of vitronectin receptor-type integrins and osteopontin in ischemia-induced retinal neovascularization. Jpn J Ophthalmol,2002,46(3):270-278.
[47].Peek, M.J., T.M. Norman, C. Morgan, et al. The chick chorioallantoic membrane assay:an improved technique for the study of angiogenic activity. Exp Pathol, 1988,34(1):35-40.
[48].Ribatti, D., B. Nico, A. Vacca, et al. The gelatin sponge-chorioallantoic membrane assay. Nat Protoc,2006,1(1):85-91.
[49].N guyen, M., Y. Shing, and J. Folkman. Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc Res, 1994.47(1):31-40.
[50].Gimbrone, M.A., Jr., R.S. Cotran, S.B. Leapman, et al. Tumor growth and neovascularization:an experimental model using the rabbit cornea. J Natl Cancer Inst,1974,52(2):413-427.
[51].Ziche, M., G. Alessandri, and P.M. Gullino. Gangliosides promote the angiogenic response. Lab Invest,1989,61(6):629-634.
[52].Kenyon, B.M., E.E. Voest, C.C. Chen, et al. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci,1996,37(8):1625-1632.
[53].Jain, R.K., K. Schlenger, M. Hockel, et al. Quantitative angiogenesis assays: progress and problems. Nat Med,1997,3(11):1203-1208.
[54].Liotta, L.A. Cancer cell invasion and metastasis. Sci Am,1992,266(2):54-59, 62-53.
[55].Fidler, I.J. Critical factors in the biology of human cancer metastasis: twenty-eighth GH.A. Clowes memorial award lecture. Cancer Res,1990,50(19): 6130-6138.
[56].Chambers, A.F., I.C. MacDonald, E.E. Schmidt, et al. Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev,1995, 14(4):279-301.
[57].Liotta, L.A., P.S. Steeg, and W.G. Stetler-Stevenson. Cancer metastasis and angiogenesis:an imbalance of positive and negative regulation. Cell,1991,64(2): 327-336.
[58].Torosian, M.H. and R.B. Donoway. Growth hormone inhibits tumor metastasis. Cancer,1991,67(9):2280-2283.
[59].Fidler, I.J. Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev,1986,5(1): 29-49.
[60].Liotta, L.A. Tumor invasion and metastases--role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res,1986,46(1):1-7.
[61].Kubota, T. Metastatic models of human cancer xenografted in the nude mouse: the importance of orthotopic transplantation. J Cell Biochem,1994,56(1):4-8.
[62].Giavazzi, R., D.E. Campbell, J.M. Jessup, et al. Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice. Cancer Res,1986,46(4 Pt 2): 1928-1933.
[63].Naito, S., A.C. von Eschenbach, and I.J. Fidler. Different growth pattern and biologic behavior of human renal cell carcinoma implanted into different organs of nude mice. J Natl Cancer Inst,1987,78(2):377-385.
[64].Niederkorn, J., J.W. Streilein, and J.A. Shadduck. Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. Invest Ophthalmol Vis Sci,1981,20(3):355-363.
[65].Theodorescu, D., I. Cornil, B.J. Fernandez, et al. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc Natl Acad Sci U S A,1990,87(22):9047-9051.
[66].Meschter, C.L., J.M. Connolly, and D.P. Rose. Influence of regional location of the inoculation site and dietary fat on the pathology of MDA-MB-435 human breast cancer cell-derived tumors grown in nude mice. Clin Exp Metastasis,1992, 10(3):167-173.
[67].Howard, R.B., H. Chu, B.E. Zeligman, et al. Irradiated nude rat model for orthotopic human lung cancers. Cancer Res,1991,51(12):3274-3280.
[68].Fridman, R., G. Giaccone, T. Kanemoto, et al. Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci U S A,1990,87(17): 6698-6702.
[69].Picard, O., Y. Rolland, and M.F. Poupon. Fibroblast-dependent tumorigenicity of cells in nude mice:implication for implantation of metastases. Cancer Res,1986, 46(7):3290-3294.
[70].Folkman, J. and M. Klagsbrun. Angiogenic factors. Science,1987,235(4787): 442-447.
[71].Hori, K., M. Suzuki, S. Tanda, et al. Characterization of heterogeneous distribution of tumor blood flow in the rat. Jpn J Cancer Res,1991,82(1): 109-117.
[72].Takano, S., K. Tsuboi, Y. Tomono, et al. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer,2000,82(12):1967-1973.
[73].Soga, N., J.O. Connolly, M. Chellaiah, et al. Rac regulates vascular endothelial growth factor stimulated motility. Cell Commun Adhes,2001,8(1):1-13.
[74].Patarca, R., G.J. Freeman, R.P. Singh, et al. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med,1989,170(1):145-161.
[75].Sodek, J., B. Ganss, and M.D. McKee. Osteopontin. Crit Rev Oral Biol Med, 2000,11(3):279-303.
[76].Katagiri, Y.U., J. Sleeman, H. Fujii, et al. CD44 variants but not CD44s cooperate with betal-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res,1999,59(1):219-226.
[77].Thayer, J.M. and G.C. Schoenwolf. Early expression of Osteopontin in the chick is restricted to rhombomeres 5 and 6 and to a subpopulation of neural crest cells that arise from these segments. Anat Rec,1998,250(2):199-209.
[78].Suzuki, K. [Osteopontin-gene, structure and biosynthesis]. Nippon Rinsho,2005, 63 Suppl 10:608-612.
[79].Thompson, J.D., D.G. Higgins, and T.J. Gibson. CLUSTAL W:improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res,1994,22(22):4673-4680.
[80].Ganss, B., R.H. Kim, and J. Sodek. Bone sialoprotein. Crit Rev Oral Biol Med, 1999,10(1):79-98.
[81].Chang, P.L., M. Cao, and P. Hicks. Osteopontin induction is required for tumor promoter-induced transformation of preneoplastic mouse cells. Carcinogenesis, 2003,24(11):1749-1758.
[82].Philip, S., A. Bulbule, and G.C. Kundu. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem,2001,276(48):44926-44935.
[83].Fedarko, N.S., A. Jain, A. Karadag, et al. Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. Faseb J,2004,18(6):734-736.
[84].Aznavoorian. S., A.N. Murphy, W.G. Stetler-Stevenson, et al. Molecular aspects of tumor cell invasion and metastasis. Cancer,1993,71(4):1368-1383.
[85].Angelucci, A., C. Festuccia, G.L. Gravina, et al. Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. Prostate,2004,59(2):157-166.
[86].Wu, Y., D.T. Denhardt, and S.R. Rittling. Osteopontin is required for full expression of the transformed phenotype by the ras oncogene. Br J Cancer,2000, 83(2):156-163.
[87].Nam, T.J., W.H. Busby, Jr., C. Rees, et al. Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth. Endocrinology,2000,141(3):1100-1106.
[88].Huang, W., B. Carlsen, G. Rudkin, et al. Osteopontin is a negative regulator of proliferation and differentiation in MC3T3-E1 pre-osteoblastic cells. Bone,2004, 34(5):799-808.
[89].Perrien, D.S., E.C. Brown, J. Aronson, et al. Immunohistochemical study of osteopontin expression during distraction osteogenesis in the rat. J Histochem Cytochem,2002,50(4):567-574.
[90].Rittling, S.R. and A.F. Chambers. Role of osteopontin in tumour progression. Br J Cancer,2004,90(10):1877-1881.
[91].Brown, L.F., A. Papadopoulos-Sergiou, B. Berse, et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol,1994,145(3):610-623.
[92].Tuck, A.B., B.E. Elliott, C. Hota, et al. Osteopontin-induced, integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor (Met). J Cell Biochem,2000,78(3):465-475.
[93].Bellahcene, A. and V. Castronovo. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol, 1995,146(1):95-100.
[94].Ue, T., H. Yokozaki, Y. Kitadai, et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer,1998,79(2):127-132.
[95].Saitoh, Y., J. Kuratsu, H. Takeshima, et al. Expression of osteopontin in human glioma.Its correlation with the malignancy. Lab Invest,1995,72(1):55-63.
[96].Donati, V., L. Boldrini, M. Dell'Omodarme, et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res,2005, 11(18):6459-6465.
[97].Rudland. P.S., A. Platt-Higgins, M. El-Tanani, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res, 2002,62(12):3417-3427.
[98].Le, Q.T., P.D. Sutphin, S. Raychaudhuri, et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res,2003,9(1):59-67.
[99].Yeatman, T.J. and A.F. Chambers. Osteopontin and colon cancer progression. Clin Exp Metastasis,2003,20(1):85-90.
[100].Kon, S., M. Maeda, T. Segawa, et al. Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem, 2000,77(3):487-498.
[101].Wai, P.Y., Z. Mi, H. Guo, et al. Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis,2005,26(4):741-751.
[102].Halatsch, M.E., U. Schmidt, I.C. Botefur, et al. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA. J Neurosurg,2000,92(2):297-305.
[103].Gibson, S.A., C. Pellenz, R.E. Hutchison, et al. Induction of apoptosis in oral cancer cells by an anti-bcl-2 ribozyme delivered by an adenovirus vector. Clin Cancer Res,2000,6(1):213-222.
[104].Suzuki, T., B. Anderegg, T. Ohkawa, et al. Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells. Gene Ther,2000,7(3):241-248.
[105].Funato, T., T. Ishii, M. Kambe, et al. Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells. Cancer Gene Ther,2000,7(3):495-500.
[106].Feng B., E.E. Rollo, and D.T. Denhardt. Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: evidence from cell lines down-regulated for OPN expression by a targeted ribozyme. Clin Exp Metastasis,1995,13(6):453-462.
[107].Behrend, E.I., A.M. Craig, S.M. Wilson, et al. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res, 1994,54(3):832-837.
[108].Behrend, E.I.,A.M. Craig, S.M. Wilson, et al. Expression of antisense osteopontin RNA in metastatic mouse fibroblasts is associated with reduced malignancy. Ann N Y Acad Sci,1995,760:299-301.
[109].Brown, P.D. Matrix metalloproteinase inhibitors. Breast Cancer Res Treat,1998, 52(1-3):125-136.
[110].Helfrich, M.H., S.A. Nesbitt, E.L. Dorey, et al. Rat osteoclasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a beta 3 integrin. J Bone Miner Res,1992, 7(3):335-343.
[111].Pettersson, E., B. Luning, H. Mickos, et al. Synthesis, NMR and function of an O-phosphorylated peptide, comprising the RGD-adhesion sequence of osteopontin. Acta Chem Scand,1991,45(6):604-608.
[112].Furger, K.A., A.L. Allan, S.M. Wilson, et al. Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res,2003,1(11):810-819.
[113].Ariztia, E.V., V. Subbarao, D.B. Solt, et al. Osteopontin contributes to hepatocyte growth factor-induced tumor growth and metastasis formation. Exp Cell Res,2003,288(2):257-267.
[114].Denhardt, D.T., D. Mistretta, A.F. Chambers, et al. Transcriptional regulation of osteopontin and the metastatic phenotype:evidence for a Ras-activated enhancer in the human OPN promoter. Clin Exp Metastasis,2003,20(1):77-84.
[115].Wang, D., S. Yamamoto, N. Hijiya, et al. Transcriptional regulation of the human osteopontin promoter:functional analysis and DNA-protein interactions. Oncogene,2000,19(50):5801-5809.
[116].Winter, G., A.D. Griffiths, R.E. Hawkins, et al. Making antibodies by phage display technology. Annu Rev Immunol,1994,12:433-455.
[117].Orlandi, R., D.H. Gussow, P.T. Jones, et al. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci U SA,1989,86(10):3833-3837.
[118].Better, M., C.P. Chang, R.R. Robinson, et al. Escherichia coli secretion of an active chimeric antibody fragment. Science,1988,240(4855):1041-1043.
[119].Barbas, C.F.,3rd, A.S. Kang. R.A. Lerner, et al. Assembly of combinatorial antibody libraries on phage surfaces:the gene Ⅲ site. Proc Natl Acad Sci U S A, 1991,88(18):7978-7982.
[120].Kang, A.S., C.F. Barbas, K.D. Janda, et al. Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces. Proc Natl Acad Sci U S A,1991,88(10):4363-4366.
[121].Sblattero, D. and A. Bradbury. A definitive set of oligonucleotide primers for amplifying human V regions. Immunotechnology,1998,3(4):271-278.
[122].Horton, R.M., Z.L. Cai, S.N. Ho, et al. Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. Biotechniques,1990, 8(5):528-535.
[123].Kim, S.H., C.C. Titlow, and M.N. Margolies. An approach for preventing recombination-deletion of the 40-50 anti-digoxin antibody V(H) gene from the phage display vector pComb3. Gene,2000,241(1):19-25.
[124]. Smith, G.P. and J.K. Scott. Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol,1993,217:228-257.
[125].Ridgway, J.B., E. Ng, J.A. Kern, et al. Identification of a human anti-CD55 single-chain Fv by subtractive panning of a phage library using tumor and nontumor cell lines. Cancer Res,1999,59(11):2718-2723.
[126].Jung, S., K.M. Arndt, K.M. Muller, et al. Selectively infective phage (SIP) technology:scope and limitations. J Immunol Methods,1999,231(1-2): 93-104.
[127].Benhar, I., R. Azriel, L. Nahary, et al. Highly efficient selection of phage antibodies mediated by display of antigen as Lpp-OmpA' fusions on live bacteria. J Mol Biol,2000,301(4):893-904.
[128]. Waterhouse, P., A.D. Griffiths, K.S. Johnson, et al. Combinatorial infection and in vivo recombination:a strategy for making large phage antibody repertoires. Nucleic Acids Res,1993,21(9):2265-2266.
[129].Perelson, A.S. and G.F. Oster. Theoretical studies of clonal selection:minimal antibody repertoire size and reliability of self-non-self discrimination. J Theor Biol, 1979,81(4):645-670.
[130].Sblattero, D. and A. Bradbury.Exploiting recombination in single bacteria to make large phage antibody libraries. Nat Biotechnol,2000,18(1):75-80.
[131].Marks, J.D., H.R. Hoogenboom, T.P. Bonnert, et al. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol,1991, 222(3):581-597.
[132].Chester, K.A., R.H. Begent, L. Robson, et al.Phage libraries for generation of clinically useful antibodies. Lancet,1994,343(8895):455-456.
[133].Barbas, C.F.,3rd, J.D. Bain, D.M. Hoekstra, et al. Semisynthetic combinatorial antibody libraries:a chemical solution to the diversity problem. Proc Natl Acad Sci USA,1992,89(10):4457-4461.
[134].Knappik, A., L. Ge, A. Honegger, et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol,2000,296(1):57-86.
[135].Griffiths, A.D., S.C. Williams, O. Hartley, et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. Embo J,1994,13(14): 3245-3260.
[136].Sheets, M.D., P. Amersdorfer, R. Finnern, et al. Efficient construction of a large nonimmune phage antibody library:the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci U S A,1998, 95(11):6157-6162.
[137].Burton, D.R., C.F. Barbas,3rd, M.A. Persson, et al.A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci U S A,1991,88(22):10134-10137.
[138].Cai, X. and A. Garen. A melanoma-specific VH antibody cloned from a fusion phage library of a vaccinated melanoma patient. Proc Natl Acad Sci U S A, 1996,93(13):6280-6285.
[139].Hennecke, F., C. Krebber, and A. Pluckthun. Non-repetitive single-chain Fv linkers selected by selectively infective phage (SIP) technology. Protein Eng, 1998,11(5):405-410.
[140].Coia, G., A. Ayres, G.G Lilley, et al. Use of mutator cells as a means for increasing production levels of a recombinant antibody directed against Hepatitis B. Gene,1997,201(1-2):203-209.
[141].Saviranta, P., M. Pajunen, P. Jauria, et al.Engineering the steroid-specificity of an anti-17beta-estradiol Fab by random mutagenesis and competitive phage panning. Protein Eng,1998,11(2):143-152.